'Peering over a conference table in Stockholm, Osswald admits #neuroscience is risky for drugmakers. “It’s a difficult area. But the benefit can be so huge when you have something which is successful,” she says.'

https://www.ft.com/content/28bd7d74-75c9-48d6-8505-717e9f56ca98